Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$79.99
-4.9%		$89.02
$44.42
▼
$151.02
$4.12B0.19798,986 shs739,309 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$12.90
-3.6%		$16.13
$5.95
▼
$62.75
$1.14B1.041.46 million shs2.00 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$18.03
-6.8%		$19.26
$4.32
▼
$21.27
$4.24B1.693.29 million shs4.71 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.27
-5.7%		$11.32
$6.28
▼
$13.11
$4.06B-0.17359,219 shs462,721 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+0.12%+1.69%-10.08%-12.74%+60.22%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+6.61%+9.67%-15.10%-33.10%-75.66%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+6.38%+2.00%-0.46%+7.31%+326.21%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+5.66%-6.86%+5.47%+9.63%+18.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$79.99
-4.9%		$89.02
$44.42
▼
$151.02
$4.12B0.19798,986 shs739,309 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$12.90
-3.6%		$16.13
$5.95
▼
$62.75
$1.14B1.041.46 million shs2.00 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$18.03
-6.8%		$19.26
$4.32
▼
$21.27
$4.24B1.693.29 million shs4.71 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.27
-5.7%		$11.32
$6.28
▼
$13.11
$4.06B-0.17359,219 shs462,721 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+0.12%+1.69%-10.08%-12.74%+60.22%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+6.61%+9.67%-15.10%-33.10%-75.66%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+6.38%+2.00%-0.46%+7.31%+326.21%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+5.66%-6.86%+5.47%+9.63%+18.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
2.83
Moderate Buy$154.7593.46% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.44
Hold$24.5790.48% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.93
Moderate Buy$25.9243.74% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$20.5081.90% Upside

Current Analyst Ratings Breakdown

Latest MLTX, CELC, TLX, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
9/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Moderate Buy
9/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$157.00
9/16/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/15/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/14/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
9/2/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/1/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/21/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$15.35M257.40N/AN/A$3.27 per share5.51
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.76$0.04 per share283.42$1.23 per share9.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$276.48M-$1.57N/AN/AN/AN/A-42.27%-38.67%11/5/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A86.69N/AN/AN/AN/AN/A

Latest MLTX, CELC, TLX, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
8/6/2026Q2 2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.3911-$0.41-$0.0189-$0.41$0.96 million$0.35 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.27
18.27
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
5.04%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
15548.93 million42.41 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
192219.14 million208.10 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.78 millionN/AN/A

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why
September 23 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-shares-gap-down-heres-why-2026-09-23/
Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush
September 23 at 8:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-telix-pharmaceuticals-nasdaq-tlx-receives-outperform-rating-from-wedbush-2026-09-23/
What could Telix Pharmaceuticals (ASX:TLX) mean for Healthcare Stocks?
September 23 at 1:55 AM  |  kalkinemedia.comK
Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach
September 23 at 1:55 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-pharmaceuticals-asx-tlx-lands-201701021.html
Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply
September 22 at 7:11 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/telix-tlx-to-buy-germanys-itm-for-up-to-2-35-billion-to-lock-in-its-cancer-isotope-supply-1842281/
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript
September 22 at 7:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4948795-telix-pharmaceuticals-limited-tlx-discusses-strategic-overview-and-oncology-pipeline-at
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day - Slideshow
September 22 at 4:42 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4948796-telix-pharmaceuticals-limited-tlx-discusses-strategic-overview-and-oncology-pipeline-at
Herbert Smith Freehills Kramer advises Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies Munich SE
September 22 at 10:51 AM  |  legaldesire.comL
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up After Analyst Upgrade
September 22 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-shares-gap-up-after-analyst-upgrade-2026-09-22/
Telix Pharmaceuticals (NASDAQ:TLX) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating
September 22 at 7:29 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-telix-pharmaceuticals-nasdaq-tlx-upgraded-by-royal-bank-of-canada-to-moderate-buy-rating-2026-09-22/
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
September 22 at 7:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4948572-telix-pharmaceuticals-limited-tlx-m-and-a-call-transcript
Is Telix's Isotope Takeover Behind Its Share Slide (ASX:TLX)?
September 22 at 5:51 AM  |  kalkinemedia.comK
ASX Preview: Australian Shares to Rise as Oil Prices Retreat; Telix Pharmaceuticals Receives ASX Waivers on Share Issuance Timing for Acquisition Consideration
September 21 at 10:53 PM  |  au.finance.yahoo.comhttps://au.finance.yahoo.com/news/asx-preview-australian-shares-rise-000402944.html
What is this broker's view on Telix shares after yesterday's crash?
September 21 at 10:53 PM  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/what-is-this-broker-s-view-on-telix-shares-after-yesterday-s-crash/ar-AA2cIiNG
Telix and ITM merge to create a radiopharmaceutical powerhouse
September 21 at 5:52 PM  |  thepharmaletter.comT
Telix Pharmaceuticals Shares Down Double Digits: Here’s Why
September 21 at 5:52 PM  |  thebull.com.auT
Telix Pharmaceuticals Limited agreed to acquire ITM Isotope Technologies Munich SE for $2.3 billion .
September 21 at 12:51 PM  |  marketscreener.comM
Telix Stock Drops 10% Following ITM Isotope Merger Deal
September 21 at 12:51 PM  |  rttnews.comhttps://www.rttnews.com/3692659/telix-stock-drops-10-following-itm-isotope-merger-deal.aspx
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion
September 21 at 12:51 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-buy-germany-apos-itm-111730818.html
Telix beefs up radioisotopes supply with $2.35 billion deal; shares crash
September 21 at 12:51 PM  |  msn.comhttps://www.msn.com/en-us/news/other/telix-beefs-up-radioisotopes-supply-with-235-billion-deal-shares-crash/ar-AA2cG8NC
Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?
September 21 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-sees-large-volume-increase-still-a-buy-2026-09-21/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$79.99 -4.11 (-4.89%)
Closing price 04:00 PM Eastern
Extended Trading
$80.16 +0.17 (+0.21%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$12.90 -0.48 (-3.59%)
Closing price 04:00 PM Eastern
Extended Trading
$12.92 +0.01 (+0.12%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$18.03 -1.32 (-6.82%)
Closing price 04:00 PM Eastern
Extended Trading
$18.41 +0.38 (+2.11%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$11.27 -0.68 (-5.69%)
Closing price 04:00 PM Eastern
Extended Trading
$11.70 +0.43 (+3.81%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas